FRANKFURT -On Tuesday, Fresenius Medical (TASE:BLWV) Care (NYSE:FMS) reported fourth quarter earnings that fell short of analyst expectations.
The stock edged higher by 1.12% in premarket trading as the company provided an upbeat outlook for 2025.
The world’s largest provider of dialysis products and services said Q4 earnings per share came in at EUR0.23, missing the analyst estimate of EUR0.49. Revenue for the quarter was EUR5.09 billion, below the consensus forecast of EUR6.02 billion.
Despite the earnings miss, Fresenius Medical Care’s shares rose 1.12% in early trading, likely buoyed by the company’s positive guidance for 2025.
For 2025, Fresenius Medical Care expects revenue growth to be positive to a low-single digit percent rate compared to the prior year. The company also projects operating income to grow by a high-teens to high-twenties percent rate.
"Fresenius Medical Care has again delivered against its commitments and we met the top end of our 2024 target to profitably grow our business," said CEO Helen Giza. "We are confident in the continued execution of our 2025 strategy."
The company said it achieved EUR567 million in accumulated savings from its FME25 transformation program in 2024, ahead of schedule. It raised the program’s 2025 savings target to EUR750 million from EUR650 million previously.
Fresenius Medical Care also reported progress on optimizing its portfolio, including exiting clinic operations in multiple markets during 2024. The company said it used proceeds from divestitures to reduce its net leverage ratio from 3.2x to 2.9x by the end of 2024.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.